D

Diffusion Pharmaceuticals Inc
NASDAQ:CRVO

Watchlist Manager
Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
Watchlist
Price: 7.98 USD -8.9% Market Closed
Market Cap: 65.9m USD
Have any thoughts about
Diffusion Pharmaceuticals Inc?
Write Note

Diffusion Pharmaceuticals Inc
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Diffusion Pharmaceuticals Inc
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
D
Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
Total Receivables
$264.2k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Receivables
$11.5B
CAGR 3-Years
7%
CAGR 5-Years
16%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Total Receivables
$4.6B
CAGR 3-Years
0%
CAGR 5-Years
7%
CAGR 10-Years
5%
Amgen Inc
NASDAQ:AMGN
Total Receivables
$7.3B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
12%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Receivables
$1.8B
CAGR 3-Years
17%
CAGR 5-Years
32%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Receivables
$6.1B
CAGR 3-Years
4%
CAGR 5-Years
18%
CAGR 10-Years
21%
No Stocks Found

Diffusion Pharmaceuticals Inc
Glance View

Market Cap
65.9m USD
Industry
Biotechnology

Diffusion Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Charlottesville, Virginia and currently employs 16 full-time employees. The company went IPO on 2016-11-09. Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development of therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed. The Company’s product candidate, Trans Sodium Crocetinate (TSC), is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The firm is focused on the development of TSC for the treatment of hypoxia and as a platform to enhance standard-of-care treatment for conditions complicated by hypoxia with a particular near-term focus on hypoxic solid tumors. Hypoxia is associated with the pathophysiology of many acute and chronic conditions including cancers, heart attack, stroke, ARDS, skin and soft tissue diseases, neurodegenerative diseases and other intractable and difficult-to-treat conditions, further complicating treatment of the underlying condition by medical providers.

CRVO Intrinsic Value
9.55 USD
Undervaluation 16%
Intrinsic Value
Price
D

See Also

What is Diffusion Pharmaceuticals Inc's Total Receivables?
Total Receivables
264.2k USD

Based on the financial report for Sep 30, 2024, Diffusion Pharmaceuticals Inc's Total Receivables amounts to 264.2k USD.

Back to Top